^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Published date:
    09/28/2021
    Excerpt:
    First-line treatment for advanced ccRCC...Sunitinib [I, A], pazopanib [I, A] and tivozanib [II, B; ESMO-MCBS v1.1 score: 1] are alternatives to PD-1 inhibitor-based first-line combinations when immune therapy is contraindicated or not available.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    The NCCN Kidney Cancer Panel has listed pazopanib as a category 1 preferred option for first-line treatment of patients with favourable risk features with relapsed or medically unresectable clear cell stage IV RCC.